These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 7480004

  • 1. Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.
    Sullivan JP, Decker MW, Donnelly-Roberts D, Brioni JD, Bannon AW, Holladay MW, Anderson DJ, Briggs CA, Williams M, Arneric SP.
    Proc West Pharmacol Soc; 1995; 38():127-30. PubMed ID: 7480004
    [Abstract] [Full Text] [Related]

  • 2. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS.
    J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
    [Abstract] [Full Text] [Related]

  • 3. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.
    Warpman U, Nordberg A.
    Neuroreport; 1995 Nov 27; 6(17):2419-23. PubMed ID: 8747166
    [Abstract] [Full Text] [Related]

  • 4. Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands.
    Briggs CA, McKenna DG, Piattoni-Kaplan M.
    Neuropharmacology; 1995 Jun 27; 34(6):583-90. PubMed ID: 7566493
    [Abstract] [Full Text] [Related]

  • 5. The pharmacology of (-)-nicotine and novel cholinergic channel modulators.
    Brioni JD, Decker MW, Sullivan JP, Arneric SP.
    Adv Pharmacol; 1997 Jun 27; 37():153-214. PubMed ID: 8891102
    [Abstract] [Full Text] [Related]

  • 6. Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist.
    Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, Suto C, Washburn M, Lloyd GK, McDonald IA.
    Pharm Acta Helv; 2000 Mar 27; 74(2-3):125-30. PubMed ID: 10812948
    [Abstract] [Full Text] [Related]

  • 7. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys.
    Prendergast MA, Jackson WJ, Terry AV, Decker MW, Arneric SP, Buccafusco JJ.
    Psychopharmacology (Berl); 1998 Mar 27; 136(1):50-8. PubMed ID: 9537682
    [Abstract] [Full Text] [Related]

  • 8. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT.
    J Pharmacol Exp Ther; 1994 Jul 27; 270(1):319-28. PubMed ID: 7913497
    [Abstract] [Full Text] [Related]

  • 9. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
    Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J.
    Alzheimer Dis Assoc Disord; 1995 Jul 27; 9 Suppl 2():50-61. PubMed ID: 8534424
    [Abstract] [Full Text] [Related]

  • 10. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
    Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1997 Oct 27; 283(1):235-46. PubMed ID: 9336329
    [Abstract] [Full Text] [Related]

  • 11. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current.
    Alkondon M, Albuquerque EX.
    J Pharmacol Exp Ther; 1995 Aug 27; 274(2):771-82. PubMed ID: 7543571
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist.
    Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan 27; 280(1):373-83. PubMed ID: 8996218
    [Abstract] [Full Text] [Related]

  • 13. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats.
    Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.
    J Pharmacol Exp Ther; 1997 Jan 27; 280(1):384-92. PubMed ID: 8996219
    [Abstract] [Full Text] [Related]

  • 14. Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats.
    Sacaan AI, Menzaghi F, Dunlop JL, Correa LD, Whelan KT, Lloyd GK.
    J Pharmacol Exp Ther; 1996 Feb 27; 276(2):509-15. PubMed ID: 8632316
    [Abstract] [Full Text] [Related]

  • 15. Attentional effects of nicotinic agonists in rats.
    Hahn B, Sharples CG, Wonnacott S, Shoaib M, Stolerman IP.
    Neuropharmacology; 2003 Jun 27; 44(8):1054-67. PubMed ID: 12763099
    [Abstract] [Full Text] [Related]

  • 16. The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.
    Rodrigues AD, Ferrero JL, Amann MT, Rotert GA, Cepa SP, Surber BW, Machinist JM, Tich NR, Sullivan JP, Garvey DS.
    Drug Metab Dispos; 1994 Jun 27; 22(5):788-98. PubMed ID: 7530622
    [Abstract] [Full Text] [Related]

  • 17. Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats.
    Decker MW, Curzon P, Brioni JD, Arnerić SP.
    Eur J Pharmacol; 1994 Aug 11; 261(1-2):217-22. PubMed ID: 8001648
    [Abstract] [Full Text] [Related]

  • 18. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.
    Grupe M, Grunnet M, Bastlund JF, Jensen AA.
    Basic Clin Pharmacol Toxicol; 2015 Mar 11; 116(3):187-200. PubMed ID: 25441336
    [Abstract] [Full Text] [Related]

  • 19. GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation.
    Kox M, van Velzen JF, Pompe JC, Hoedemaekers CW, van der Hoeven JG, Pickkers P.
    Biochem Pharmacol; 2009 Oct 01; 78(7):863-72. PubMed ID: 19576181
    [Abstract] [Full Text] [Related]

  • 20. The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia.
    Thomsen MS, Mikkelsen JD.
    J Neuroimmunol; 2012 Oct 15; 251(1-2):65-72. PubMed ID: 22884467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.